Multiple Pregnancy (twins incl. TTTS/TAPS/TRAP)
Clinical detail
Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.
Chorionicity and amnionicity determine the surveillance pathway for multiple pregnancy. A twin pregnancy should not be managed as two routine singleton pregnancies.
Assessment & interpretation
- Determine and record gestational age, chorionicity and amnionicity at the first-trimester scan.
- Label the fetuses consistently so that growth and Doppler trends can be compared across visits.
Decisions that change management
- Shared-placenta pregnancies need specific surveillance for complications such as twin-to-twin transfusion.
- NICE offers ultrasound monitoring for feto-fetal transfusion every 14 days from 16 weeks until birth in monochorionic pregnancy, with escalation when fluid or growth concerns arise.
- Coordinate care with a team experienced in multiple pregnancy and refer suspected complications to fetal medicine.
Follow-up & safety-netting
- Assess maternal blood pressure and anaemia and discuss preterm-birth symptoms.
- Document a personalised plan for surveillance, birth timing, place of birth and neonatal support; the plan depends on chorionicity and complications.
Clinical pitfalls
- Growth discordance and an individual fetus’s growth restriction are related but separate findings. A single estimated-weight difference does not replace review of growth trend, fluid and Doppler findings.
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Admit preterm labour, bleeding, membrane rupture, maternal illness or fetal concern; suspected TTTS/TAPS or other monochorionic complications needs urgent fetal-medicine assessment.
When clinic, day care or home care may be suitable
- An uncomplicated multiple pregnancy does not by itself require continuous hospital admission; chorionicity determines surveillance and birth planning.
Before going home
- The reason for assessment is resolved or has an agreed specialist plan; chorionicity, current findings and the next surveillance date are explicit.
- After birth, assess each baby separately and complete the actual maternal delivery/complication pathway.
Discharge medicines and treatment changes
- Reconcile indicated supplements and other prescribed medicines; do not prescribe routine home tocolysis simply because the pregnancy is multiple.
Tests, pending results and their reviewer
- Record each fetus’s findings, chorionicity and scan plan; ensure the family knows which service reviews results.
Home care and counselling
- Discuss preterm-labour symptoms, fetal movement concerns, feeding/support and planned birth/neonatal capacity.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
At the chorionicity-specific appointments | Continue the named specialist schedule; increase intensity for a diagnosed complication. |
Before planned birth | Confirm date/place, fetal presentations and neonatal/anaesthetic plans. |
Return urgently
- Contractions, bleeding, fluid loss, reduced movements, severe headache or breathlessness requires maternity assessment.
Treatment
① Immediate stabilization — first minutes
TTTS stages II+: fetoscopic laser coagulation at specialised centre (survival benefit) - refer immediately.
③ First-line treatment & drug regimens
| Type | Surveillance | Delivery timing |
|---|---|---|
DCDA | US q4 wks from 16 wks (growth/fluid) | 37-38 wks (elective) |
MCDA | US q2 wks from 16 wks (fluid discordance, EFW, MCA-PSV) | ~36-37 wks (range 34-37 individualised) |
MCMA | Inpatient from ~26-28 wks; frequent US/CTG | ~32-34 wks after steroids |
- Imminent preterm birth within the guideline gestational window; do not delay urgent maternal/fetal delivery
- NICE offers at 24+0–33+6 weeks, considers 34+0–35+6; individual discussion at 22+0–23+6. Repeat: <34 weeks, prior course >7 days ago and very high risk of birth in 48 h.
- Glucose monitoring and an insulin-adjustment plan in diabetes; assess infection and timing of birth
④ Drug treatment detail (2 agents)
- Indication: Alternative fetal-lung-maturation course when appropriate
- Maternal glucose, infection assessment and birth timing; diabetes team plan
- Indication: Imminent preterm birth: NICE offers at 24+0–29+6 weeks and considers at 30+0–33+6 weeks; discuss 23+0–23+6 individually
- Record pulse, BP, respiratory rate and tendon reflexes at least every 4 h; more often if oliguria or renal impairment
Definitive treatment
Planned timed birth; TTTS laser; selective procedures (reduction/coagulation) for complicated MC cases at expert centres.
Monitoring
- Calendar-driven scans (audit-friendly)
- BP surveillance (twin pregnancies higher PET risk)
- GBS/steroids plans before each window
Response assessment
- Stable discordance <20%, fluids symmetric, growth curves parallel
Treatment failure
- Emerging TTTS/sFGR signs -> immediate fetal-medicine contact
Escalation
- ALL monochorionic complications to tertiary fetal-medicine units
- NICU capacity confirmed before scheduled preterm births
⑮ Complications & their management
TTTS
Quintero staging; laser for II+; serial amnioreduction bridge only
Single intrauterine death
Co-twin surveillance (brain injury risk esp. MC): MRI/neuroimaging plan + delivery timing decision
Postpartum haemorrhage
Overdistended uterus: prophylactic oxytocin infusion standard; PPH bundle ready
Preterm birth
PTL pathways apply; steroids timing per twin-specific windows
Post-treatment care
- Standard recovery + lactation support (twins breastfeeding feasible - support!)
- Contraception counselling
- Next-pregnancy counselling (recurrence modest; IVF-related factors)
Diagnosis & assessment
- MC polyhydramnios-oligohydramnios sequence -> TTTS referral NOW
- Discordant EFW >25% (sFGR)
- One twin demise (co-twin injury risk)
- Any MC complication -> fetal-medicine centre referral
Definition: DCDA/MCDA/MCMA classifications determine surveillance intensity and complications (TTTS Quintero staging, TAPS MCA-PSV delta, TRAP/acardiac, sFGR).
Initial assessment
- Label chorionicity/amnionicity EARLY (lambda vs T-sign)
- Schedule surveillance calendar per type
- Anaemia screening + iron optimisation (higher demands)
- Mode-of-birth planning: vertex/vertex vaginal reasonable DCDA uncomplicated
Investigations
| Test | Looking for |
|---|---|
CRL/crown-rump + NT 11-13+6 | Dating + chorionicity + aneuploidy risk |
Serial EFW discordance | >20-25% triggers escalation |
MCA-PSV (MC pairs) | TAPS (>0.5 MoM delta)/anaemia screening |
Principles & follow-up
Management principles
Sources (9)
2022-02 · checked 2026-08-23 · pending-verification
Open source ↗
Cited via RCOG GTG73 update note; direct PDF audit pending — flag
04 September 2019 · updated 09 April 2024 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for multiples. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check …
· checked 2026-10-17 · verified-summary
Open source ↗
Recommendation 1.9/type-and-regimen evidence: IM dexamethasone or betamethasone total 24 mg; four 6 mg dexamethasone doses 12 hours apart or two 12 mg betamethasone doses 24 hours apart. NICE NG25 supplies gestational and repeat-course criteria.
20 November 2015 · updated 10 June 2022 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for ptl-threatened, ptl-established. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admi…
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.